课题基金 / 基金详情

PQ6: Transgenic Mouse Model for Kaposi Sarcoma

PQ6: Transgenic Mouse Model for Kaposi Sarcoma
PQ6:卡波西肉瘤转基因小鼠模型
批准号:
10115683
负责人:
Dirk P Dittmer
金额:
$52.16万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-03-01 至 2025-02-28

项目摘要

项目成果

Dirk P Dittmer的其他基金

相关文献

中文摘要
翻译
项目摘要 对于最常见的卡波西肉瘤(Kaposi Sarcoma,KS),经过25年的研究,至今仍没有合适的动物模型 艾滋病毒/艾滋病感染者的癌症。值得注意的是,KS甚至在HIV感染者中发展, 正常的CD 4计数和没有检测到的HIV病毒载量,以及在HIV阴性的人-所谓的经典 KS. KS相关疱疹病毒(KSHV)是KS所必需的。而不是专注于一种特定的病毒 基因,我们将完整的138,146 bp KSHV病毒基因组插入转基因小鼠。这些发展 血管肉瘤和KSHV基因在肿瘤中表达。该提案旨在了解 KS肿瘤发生的机制,并研究已知的和新的候选药物。本提案响应 NCI挑衅性问题六:“新的HIV/AIDS相关恶性肿瘤的体外和体内模型是否可以 发展研究他们的发展,发病机制,和潜在的评估, 艾滋病相关恶性肿瘤的新疗法?”
英文摘要
Project Summary Abstract After 25 years there is still is no adequate animal model for Kaposi Sarcoma (KS), which is the most common cancer in people living with HIV/AIDS world-wide. Notably, KS develops even in HIV-infected person with normal CD4 counts and no detectable HIV viral load, as well as in HIV-negative persons – so called classic KS. The KS-associated herpesvirus (KSHV) is necessary for KS. Rather than focusing on one specific viral gene, we inserted the entire 138,146 bp KSHV viral genome into transgenic mice. These develop angiosarcoma and the KSHV genes are expressed in the tumor. This proposal seeks to understand the mechanism of KS tumorigenesis and to study known and novel drug candidates. This proposal responds to NCI provocative question six: “Can novel in vitro and in vivo models of HIV/AIDS-associated malignancies be developed to study their development, pathogenesis, and the potential evaluation of novel treatments for common HIV/AIDS-associated malignancies?”
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa